Vision Monday


Eyenovia Raises $27 Million With Initial Public Stock Offering

By Staff
Monday, February 5, 2018 12:21 AM

NEW YORK—Eyenovia Inc. (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products, reported last week that it closed its initial public offering of 2,730,000 shares of its common stock. Eyenovia said it received $27.3 million in gross proceeds from the offering, before underwriting discounts and commissions, and other estimated offering expenses. Eyenovia said it is developing eyecare products that utilize its patented piezo-print technology to deliver micro-therapeutics topically to the eye. In addition, Eyenovia said it has granted the underwriters a 30-day option to purchase up to 409,500 additional shares to cover over-allotments, if any.

Eyenovia’s common shares are traded on the Nasdaq Capital Market under the ticker symbol “EYEN.” Ladenburg Thalmann & Co. and Roth Capital Partners acted as joint book-running managers for the offering, according to the announcement.
Also Recommended
Sun Pharma Receives FDA Approval for Dry Eye Drug
Vuzix Delivers Strong Revenue and Gross Profit Growth in 2Q ’18
Americans Spend 40 Percent of Awake Time at a Screen, CooperVision Survey Finds
EyePoint Pharmaceuticals Appoints John Weet to SVP, Regulatory Affairs Post
Home VM Mobile